{"version":"1.0","provider_name":"Myanmar Newswire","provider_url":"https:\/\/myanmarnewswire.com","author_name":"admin","author_url":"https:\/\/myanmarnewswire.com\/author\/admin\/","title":"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 - Myanmar Newswire","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"RkfxbU0XCG\"><a href=\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/\">Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/embed\/#?secret=RkfxbU0XCG\" width=\"600\" height=\"338\" title=\"&#8220;Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014&#8221; &#8212; Myanmar Newswire\" data-secret=\"RkfxbU0XCG\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) \u2014 Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014. In June 2019, Junshi Biosciences and Anwita [\u2026]"}